Showing results (181-190 of 317) with videos related to
Sort By:
Pageof 32
Blood|March 2, 2012
Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AMLJessica A Pollard, Todd A Alonzo, Michael Loken, et al.Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|May 5, 2021
Aberrantly low STAT3 and STAT5 responses are associated with poor outcome and an inflammatory gene expression signature in pediatric acute myeloid leukemiaP Narayanan, T-K Man, R B Gerbing, et al.Preventive Medicine|July 1, 2018
Acceptability of self-sampling and human papillomavirus testing among non-attenders of cervical cancer screening programs in El SalvadorM Maza, M Melendez, R Masch, et al.Bone Marrow Transplantation|June 15, 2007
Autologous bone marrow transplantation for children with AML in first remissionS Neudorf, J Sanders, N Kobrinsky, et al.Cancer|October 10, 2013
Outcome of adolescents and young adults with acute myeloid leukemia treated on COG trials compared to CALGB and SWOG trialsWilliam G Woods, Anna R K Franklin, Todd A Alonzo, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 3, 2017
Arsenic Trioxide Consolidation Allows Anthracycline Dose Reduction for Pediatric Patients With Acute Promyelocytic Leukemia: Report From the Children's Oncology Group Phase III Historically Controlled Trial AAML0631Matthew A Kutny, Todd A Alonzo, Robert B Gerbing, et al.Leukemia & Lymphoma|February 25, 2014
High expression of suppressor of cytokine signaling-2 predicts poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology GroupGeorge S Laszlo, Rhonda E Ries, Chelsea J Gudgeon, et al.Journal of Clinical Pharmacology|April 19, 2017
Population Pharmacokinetic Analysis of Bortezomib in Pediatric Leukemia Patients: Model-Based Support for Body Surface Area-Based Dosing Over the 2- to 16-Year Age RangeMichael J Hanley, Diane R Mould, Timothy J Taylor, et al.Pediatric Blood & Cancer|April 15, 2024
Characteristics and treatment of acute myeloid neoplasms with cutaneous involvement in infants up to 6 months of age: A retrospective studyJuliette Renaud, Bianca F Goemans, Franco Locatelli, et al.Cancer|April 29, 2014
AAML0523: a report from the Children's Oncology Group on the efficacy of clofarabine in combination with cytarabine in pediatric patients with recurrent acute myeloid leukemiaTodd M Cooper, Todd A Alonzo, Robert B Gerbing, et al.Pageof 32